SLRX [NASD]
Salarius Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.38 Insider Own0.70% Shs Outstand46.26M Perf Week0.69%
Market Cap11.11M Forward P/E- EPS next Y-0.47 Insider Trans110.42% Shs Float43.88M Perf Month-44.34%
Income-17.00M PEG- EPS next Q-0.10 Inst Own10.10% Short Float1.37% Perf Quarter-55.96%
Sales0.60M P/S18.52 EPS this Y37.90% Inst Trans-21.94% Short Ratio0.55 Perf Half Y-72.50%
Book/sh0.72 P/B0.26 EPS next Y-2.70% ROA-40.50% Target Price4.25 Perf Year-86.09%
Cash/sh0.41 P/C0.46 EPS next 5Y- ROE-42.40% 52W Range0.16 - 1.49 Perf YTD-61.82%
Dividend- P/FCF- EPS past 5Y65.20% ROI-33.10% 52W High-86.94% Beta1.37
Dividend %- Quick Ratio11.90 Sales past 5Y12.70% Gross Margin- 52W Low21.59% ATR0.04
Employees16 Current Ratio11.90 Sales Q/Q-100.00% Oper. Margin- RSI (14)41.22 Volatility19.15% 17.66%
OptionableNo Debt/Eq0.00 EPS Q/Q-117.90% Profit Margin- Rel Volume1.38 Prev Close0.19
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume1.09M Price0.19
Recom1.00 SMA20-5.86% SMA50-36.93% SMA200-68.28% Volume184,377 Change2.83%
Apr-27-20Initiated Ladenburg Thalmann Buy $3.80
May-18-22 04:10PM  
May-12-22 04:05PM  
May-11-22 04:05PM  
May-05-22 07:30AM  
Apr-22-22 08:30AM  
Mar-10-22 04:05PM  
Mar-03-22 07:31AM  
Feb-17-22 08:01AM  
Feb-15-22 09:00AM  
Feb-08-22 08:00AM  
Feb-03-22 07:30AM  
Jan-14-22 01:52PM  
Jan-13-22 07:00AM  
Jan-06-22 12:45PM  
Dec-29-21 08:03AM  
Dec-20-21 08:35AM  
Dec-15-21 08:31AM  
Dec-14-21 08:35AM  
Nov-29-21 08:01AM  
Nov-04-21 04:05PM  
Oct-28-21 03:06PM  
Oct-26-21 08:01AM  
Oct-07-21 09:05AM  
Oct-05-21 08:01AM  
Sep-30-21 04:35PM  
Sep-28-21 07:01AM  
Sep-27-21 08:03AM  
Sep-22-21 07:33AM  
Sep-20-21 08:35AM  
07:33AM  
Sep-15-21 08:03AM  
Sep-10-21 08:35AM  
Sep-08-21 08:13AM  
Aug-12-21 02:00PM  
09:00AM  
Aug-10-21 06:16AM  
Aug-05-21 07:32AM  
Jul-29-21 07:33AM  
Jul-14-21 08:05AM  
Jul-13-21 07:33AM  
Jul-09-21 07:33AM  
Jun-17-21 08:03AM  
Jun-15-21 07:30AM  
Jun-10-21 01:30PM  
Jun-07-21 07:35AM  
May-19-21 05:01PM  
May-12-21 04:05PM  
02:45PM  
May-05-21 07:05AM  
Apr-29-21 07:30AM  
Apr-19-21 07:30AM  
Mar-18-21 04:05PM  
02:30PM  
Mar-11-21 04:15PM  
Mar-08-21 04:05PM  
Mar-04-21 08:30AM  
Mar-03-21 04:05PM  
Feb-24-21 07:00AM  
Feb-22-21 07:30AM  
Feb-17-21 09:00AM  
07:30AM  
Feb-16-21 07:30AM  
Feb-10-21 06:21AM  
Jan-21-21 08:05AM  
Jan-15-21 07:30AM  
Jan-13-21 07:30AM  
Dec-22-20 07:30AM  
Dec-11-20 11:32AM  
Dec-10-20 09:28AM  
Nov-17-20 07:30AM  
Nov-11-20 04:05PM  
02:30PM  
Nov-04-20 07:30AM  
Oct-13-20 07:30AM  
Sep-21-20 08:35AM  
Sep-14-20 08:35AM  
Sep-10-20 07:30AM  
Aug-27-20 10:00AM  
Aug-12-20 04:05PM  
Aug-06-20 02:01PM  
Aug-05-20 09:30AM  
07:30AM  
Aug-03-20 04:05PM  
Jul-30-20 09:22AM  
Jul-29-20 04:15PM  
04:05PM  
Jul-28-20 08:00AM  
Jul-23-20 08:00AM  
Jun-02-20 09:00AM  
May-27-20 08:00AM  
May-22-20 09:24AM  
May-14-20 04:05PM  
08:00AM  
May-07-20 04:05PM  
Apr-29-20 07:30AM  
Apr-22-20 08:00AM  
Apr-13-20 03:15PM  
Mar-23-20 04:18PM  
Mar-04-20 08:00AM  
Mar-02-20 08:00AM  
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenblum Mark JExec VP Finance, CFOMar 03Buy0.3976,24629,812110,319Mar 09 04:03 PM
Arthur David J.Chief Executive OfficerMar 03Buy0.39139,48854,540249,674Mar 09 04:01 PM
Arthur David J.Chief Executive OfficerAug 17Buy0.904,0003,582102,247Aug 17 04:08 PM
HANISH ARNOLD CDirectorAug 10Buy0.887,0006,16718,350Aug 11 04:08 PM